We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Research · 8 min read

Vaginal dryness after menopause: lasers, vaginal estrogen and what the evidence says

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

After a recent TV mention of vaginal laser treatment, we look at genitourinary symptoms after menopause, rising vaginal estrogen dispensing, what FDA has said about energy-based devices, and nonhormonal options

On the November 19, 2026, episode of The Kardashians, Kris Jenner said she was going for a MonaLisa treatment, which she described as "a laser in your vagina" and a procedure she has had before, according to USA Today. That is all this article takes from the episode: what she said she was doing, as the newspaper reported it.

Vaginal dryness, burning, irritation and pain with sex are common after menopause. They have a clinical name, genitourinary syndrome of menopause, or GSM. Some clinics market energy-based procedures, often called vaginal "rejuvenation," for those symptoms; vaginal estrogen is a different option. This article is for education. It is not medical advice, and it is not a recommendation to start, stop or change any treatment.

What genitourinary syndrome of menopause is

The Menopause Society, in a 2020 position statement published when the organization was called The North American Menopause Society, describes GSM as the symptoms and signs that result from estrogen deficiency affecting the vagina, labia, urethra and bladder. That can include dryness, burning and irritation; urinary symptoms such as pain with urination, urgency and recurrent urinary tract infections; and pain or dryness with sex. A person may have some of these symptoms or all of them. The statement says the symptoms have to be bothersome for the syndrome to be diagnosed, and that other causes, including infection, skin conditions or cancer, need to be ruled out.

GSM is common and often goes untreated. The 2020 statement estimated that it affects about 27% to 84% of postmenopausal women, can impair sexual function and quality of life, and is likely underdiagnosed. People who are not sexually active can still have bothersome symptoms. Unlike hot flashes, which often ease with time, GSM symptoms often worsen without treatment.

The National Institute on Aging similarly describes vaginal dryness that can make sex painful and advises talking with a doctor about options.

Vaginal estrogen dispensing is climbing

On November 19, 2026, JAMA published "Trends in Menopause Hormone Therapy," a national analysis of pharmacy dispensing. Science News, reporting on that paper the same day, said monthly menopause hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, growing from 2 million to 4.9 million. The same account said product use increased for transdermal and vaginal estrogen and for progesterone products, while oral formulations remained stable.

Those counts are Science News's report of the JAMA results, not a headcount of unique people. One person can have more than one fill in a month, and a rise in dispensing is not, by itself, a reason to start or stay on a treatment. We could not independently read the JAMA full text, so we are not treating the figures as verified from the paper itself. Our November 20 post on the JAMA data explains that distinction and the access limit.

The split in the reported data still matters here. Vaginal estrogen, used for genital or urinary symptoms, is not the same as systemic hormone therapy used for hot flashes. Our guide to types of hormone therapy compares routes. What is appropriate for one person can be a poor fit for another.

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. Local vaginal estrogen is a different situation from systemic estrogen and does not automatically follow the same pairing rule; that decision belongs in a visit. The 2020 statement says that when low-dose vaginal estrogen is used, a progestogen is not indicated, though endometrial safety has not been studied in clinical trials beyond one year, and spotting or bleeding still needs evaluation. The statement also noted that, at the time, labels for low-dose vaginal estrogen carried the same boxed warning as systemic estrogen; a clinician or pharmacist can explain what the current label says.

What FDA said about energy-based "vaginal rejuvenation" devices

On July 30, 2018, FDA issued a safety communication titled "FDA Warns Against Use of Energy-Based Devices to Perform Vaginal 'Rejuvenation' or Vaginal Cosmetic Procedures." The original fda.gov page was not live when we checked on November 21, 2026. The wording below comes from an archived official copy of that communication and matches FDA manufacturer letters that remain posted on fda.gov, as well as CNN's same-day report.

FDA said the safety and effectiveness of energy-based devices — commonly radiofrequency or laser — for vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical procedures to treat symptoms related to menopause, urinary incontinence or sexual function had not been established. "To date, we have not cleared or approved for marketing any energy-based devices to treat these symptoms or conditions, or any symptoms related to menopause, urinary incontinence, or sexual function," the communication said. It warned that those uses "may lead to serious adverse events, including vaginal burns, scarring, pain during sexual intercourse, and recurring/chronic pain."

FDA also noted that some of the same kinds of devices had been cleared as general gynecologic tools for other uses, including destruction of abnormal or precancerous cervical or vaginal tissue and treatment of genital warts. That is not clearance or approval to treat menopause-related vaginal symptoms or to perform "rejuvenation." The agency told patients and clinicians to discuss the benefits and risks of available options, and it encouraged reporting of complications through MedWatch.

The same day, then-Commissioner Scott Gottlieb said FDA was "deeply concerned women are being harmed," and that deceptive marketing of unproven treatments may cause injuries and may keep some people from recognized therapies. His statement said the agency had notified seven manufacturers, including Cynosure, which marketed the MonaLisa Touch device named in the USA Today report. In a July 24, 2018, letter still posted on fda.gov, FDA told Cynosure it could not identify an additional clearance or approval supporting certain menopause-related claims for that device.

We looked for a later FDA statement that withdraws or replaces the July 2018 communication and did not find one. Later actions point in the same direction. In a February 8, 2023, warning-letter follow-up, FDA said another manufacturer's marketing of an energy-based device for vaginal atrophy, GSM and related uses was a major change in intended use for which the firm lacked clearance or approval. A September 2025 clearance we reviewed for one laser system covered general surgical soft-tissue uses, not menopause-related vaginal symptoms.

The 2020 Menopause Society statement reached a similar conclusion: energy-based devices, including lasers and radiofrequency devices, were under investigation for GSM, but none had FDA approval for that indication, and there were insufficient placebo-controlled trials to draw conclusions on efficacy and safety or to recommend routine use. The statement called for long-term, sham-controlled studies first and listed possible adverse events, including discomfort during treatment, scarring, lacerations when intercourse is resumed, and persistent or worsening pain with sex.

Nonhormonal moisturizers and lubricants

Not every GSM symptom needs a prescription, and not everyone can or wants to use hormones. The 2020 Menopause Society statement says nonhormone therapies available without a prescription provide sufficient relief for most women with mild symptoms. It distinguishes two general categories, without this article naming any brand:

  • Lubricants, used at the time of sexual activity, to reduce friction.
  • Moisturizers, used regularly, not only during sex, to help with ongoing dryness.

NIA draws the same distinction. The Menopause Society statement notes that product composition varies and that some formulations can irritate; a clinician or pharmacist can help with that choice. This is not a recommendation to start or stop any product on your own.

For moderate to severe symptoms, the same statement lists low-dose vaginal estrogens (prescription-only), vaginal DHEA, systemic estrogen therapy and ospemifene as effective options. NIA notes that FDA has approved two other prescription medications, ospemifene and prasterone, for moderate to severe pain with sex caused by vaginal changes of menopause, and that a doctor can explain the risks and benefits. Prasterone is vaginal DHEA, which the 2020 statement describes as a steroid hormone, so it is not a hormone-free option. Ospemifene (Osphena) is a pill whose label carries a boxed warning about endometrial cancer and about stroke and blood clots; it is not for people with undiagnosed abnormal genital bleeding, estrogen-dependent cancer, or a history of blood clots or stroke. Prasterone (Intrarosa) is a vaginal insert; its label notes that estrogen is a metabolite of prasterone, that it has not been studied in women with a history of breast cancer, and that it should not be used when there is undiagnosed abnormal genital bleeding. Which option belongs in a plan, if any, is a clinical decision.

When to talk with a clinician

It is reasonable to bring up vaginal dryness, pain with sex, burning, irritation or recurring urinary infections, especially if they are getting in the way of daily life or intimacy. A clinician can look for other causes and talk through nonhormonal and hormonal options. If you have a history of estrogen-dependent cancer, that history belongs in the visit; the 2020 statement says management in people with breast cancer should consider the person's needs and the recommendations of their oncologist. Our guide to who should not take hormone therapy covers contraindications and gray areas for systemic therapy; vaginal treatment is not automatically the same decision.

Bleeding after menopause is a reason to see a clinician, not a wait-and-see symptom. The 2020 Menopause Society statement gives this its strongest (Level A) recommendation: spotting or bleeding in a postmenopausal woman requires a thorough evaluation that may include transvaginal ultrasound, endometrial biopsy, or both. An ACOG expert explainer says to get in touch with your obstetrician-gynecologist right away, no matter the exact pattern of bleeding, and defines menopause as confirmed after one year since the last menstrual period. Thinning of the vaginal lining can cause bleeding, including after sex, but ACOG says a full evaluation is still needed. Do not start, stop or change a hormone treatment, including vaginal estrogen, to manage bleeding on your own.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. If you are dealing with vaginal dryness, pain with sex or related symptoms, a licensed clinician can take a history, discuss what may or may not be appropriate, from nonhormonal options to prescription treatment, and answer questions about energy-based procedures you may have seen marketed. Kindr Care patient intake is open now.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Sources

Medically reviewed by Kindr Health Clinical Team
Last updated: November 21, 2026

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you

A new JAMA analysis of pharmacy dispensing, as reported by Science News, finds monthly hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, with growth in transdermal and vaginal estrogen while pills stayed flat, and we look at what that means for planning care

Research

Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve

An AMWA position paper names gaps that still keep people from menopause care: training, screening, coverage, research and stigma. We look at what's changing in state law, a new academic post in British Columbia, and ACOG's guidance, and we offer a practical checklist for getting evaluated.

Research

Menopause care is going mainstream in state law: what's changing on coverage, education and work

Statehouses are moving on menopause coverage, education and work: what Illinois has enacted, what is pending in Pennsylvania, and what to ask your insurer. A federal survey also shows how few symptomatic women ages 40 to 60 currently take a prescription, and we look at how ACOG's new guidance fits in.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →